RxDoctor Payments Data

Laura Perry, APRN

Family · Scottsbluff, NENPI 1891204624

Payments from drug & device makers

$289in general payments, 2019–2025

Across 18 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$110
  • Tandem Diabetes Care, Inc.$36
  • Insulet Corporation$35
  • Lilly USA, LLC$27
  • BETA Bionics, Inc.$23
  • Abbott$19
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$289 in reported general payments places this provider in the 50th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$79,653
Medicare patients
200
Services billed
1,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide552$547,722
Xultophy 100-3.6Insulin Degludec/Liraglutide322$407,625
JardianceEmpagliflozin459$367,652
Tresiba Flextouch U-100Insulin Degludec193$101,022
FarxigaDapagliflozin Propanediol174$96,345
JanuviaSitagliptin Phosphate134$91,883
MounjaroTirzepatide56$57,272
RybelsusSemaglutide62$56,930
Soliqua 100-33Insulin Glargine/Lixisenatide53$51,517
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$30,160
TrulicityDulaglutide29$27,127
Fiasp FlextouchInsulin Aspart (Niacinamide)48$23,886
Tresiba Flextouch U-200Insulin Degludec32$23,656
Novolog FlexpenInsulin Aspart148$21,306
TradjentaLinagliptin29$19,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog$110$1,019,901969 claims
Boehringer IngelheimJardiance, Tradjenta$12$387,018488 claims
AstraZenecaFarxiga$14$96,345174 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$27$87,029112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 809 family providers in Nebraska.

Other family in Scottsbluff

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →